(Q83679977)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Anders E Pedersen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Mette B Jungersen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Charlotte D Pedersen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

23 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

239-245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426340%20AND%20SRC:MED&resulttype=core&format=json

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

26 January 2020

cites work

1 reference

12 December 2020

Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes

1 reference

12 December 2020

Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

1 reference

12 December 2020

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

1 reference

12 December 2020

Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Overview of monoclonal antibodies in cancer therapy: present and promise

1 reference

12 December 2020

The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes

1 reference

12 December 2020

Characterization of Monocyte-Derived Dendritic Cells Maturated With IFN-alpha

1 reference

12 December 2020

The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells

1 reference

12 December 2020

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia

1 reference

12 December 2020

Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

1 reference

12 December 2020

B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family

1 reference

12 December 2020

Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving

1 reference

12 December 2020

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

1 reference

12 December 2020

The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism

1 reference

12 December 2020